The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions ...

The pharma giant struck a licensing deal to gain access to delivery technologies developed by U.S. startup Vivtex., to deepen ...

Vivtex, cofounded by renowned MIT professor Robert Langer, stands to make as much as $2.1 billion if milestones are met.

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is ...

Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop ...

Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral ...

Danish drugmaker teams with US biotech to develop oral obesity and metabolic drugs as shares fall 63% over 12 months.

Novo Nordisk (NVO) stock is in focus as the company teams up with Vivtex in a $2.1B deal to develop next-gen oral biologics for obesity and diabetes. Read more here.

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Vivtex Corp. announced the deal with Novo Nordisk worth up to $2.1 billion to develop oral drugs for conditions like obesity and diabetes.